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Abstract The function and intracellular delivery of enzyme
therapeutics for Fabry disease were studied in cultured
fibroblasts and in the biopsied tissues of two male patients
to show diversity of affected cells in response to treatment.
In the mutant fibroblasts cultures, the final cellular level of
endocytosed recombinant α-galactosidases A (agalsidases,
Fabrazyme
TM, and Replagal
TM) exceeded, by several fold,
the amount in control fibroblasts and led to efficient direct
intra-lysosomal hydrolysis of (
3H)Gb3Cer. In contrast, in
the samples from the heart and some other tissues biopsied
after several months of enzyme replacement therapy (ERT)
with Fabrazyme
TM, only the endothelial cells were free of
storage. Persistent Gb3Cer storage was found in cardiocytes
(accompanied by increase of lipopigment), smooth muscle
cells, fibroblasts, sweat glands, and skeletal muscle.
Immunohistochemistry of cardiocytes demonstrated, for
the first time, the presence of a considerable amount of
the active enzyme in intimate contact with the storage
compartment. Factors responsible for the limited ERT
effectiveness are discussed, namely post-mitotic status of
storage cells preventing their replacement by enzyme
supplied precursors, modification of the lysosomal system
by longstanding storage, and possible relative lack of
Sap B. These observations support the strategy of early
treatment for prevention of lysosomal storage.
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Introduction
Fabry disease (MIM 301500) is an X-linked deficiency of
α-galactosidase A (α-GALA, EC 3.2.1.22) leading to
widespread lysosomal accumulation of glycosphingolipids
with terminal α-galactosyl moieties (mainly globotriaosyl-
Virchows Arch (2008) 452:651–665
DOI 10.1007/s00428-008-0586-9
J. Keslová-Veselíková, H.Hůlková and R. Dobrovolný contributed
equally to this work.
J. Keslová-Veselíková:H. Hůlková: R. Dobrovolný: B. Asfaw:
H. Poupětová: L. Berná: J. Sikora:J. Ledvinová (*):
M. Elleder (*)
Institute of Inherited Metabolic Disorders,
Bldg. D, Division B; Ke Karlovu 2, 128 08,
Prague 2, Czech Republic
e-mail: jledvin@cesnet.cz
J. Keslová-Veselíková
e-mail: jana.keslova@seznam.cz
H. Hůlková
e-mail: helena.hulkova@lf1.cuni.cz
R. Dobrovolný
e-mail: robert.dobrovolny@lf1.cuni.cz
B. Asfaw
e-mail: basfaw@cesnet.cz
H. Poupětová
e-mail: helena.poupetova@lf1.cuni.cz
L. Berná
e-mail: lindaberna@yahoo.com
J. Sikora
e-mail: jakub.sikora@lf1.cuni.cz
L. Goláň
Clinical Department of Cardiology and Angiology,
First Faculty of Medicine and University Hospital,
U nemocnice 2, 128 08, Prague 2, Czech Republic
e-mail: lubor.golan@seznam.cz
e-mail: melleder@cesnet.czceramide, Gb3Cer). The ensuing phenotype at the clinical
level is well known, including its organ-limited milder
variants in hemizygous males and in females who are
mosaic hemizygotes [9, 10]. The dominating therapeutic
approach, enzyme replacement therapy (ERT), is based on
substitution of the missing enzyme with recombinant α-
galactosidases, Fabrazyme
TM (agalsidase beta, Genzyme)
or Replagal
TM (agalsidase alfa, SHGT) [6, 13]. Despite
differences in the glycosylation pattern due to different
expression systems [14, 41], both enzymes appear to be
functionally indistinguishable from each other [3, 23]. The
essential requirement for successful ERT of Fabry disease
is the delivery of a sufficient dose of the enzyme into the
storage lysosomal compartment. The effect on storage
has been evaluated either by monitoring the level of
storage or the induction of enzyme activity [12, 21, 3,
23, 33]. However, there is not any report demonstrating
complete clearance of the storage lysosomal system
generally. The effect is mostly restricted to endothelia,
but the partial clearance effect has been seen by some
authors also in another cells, e.g., in the kidney [15].
The goal of this study was to compare effectiveness of
ERT in two cell systems: by cultured mutant fibroblasts on
one side, representing dynamic cell population minimally
modified by low degree spontaneous storage, and transiently
exposed to trace amount of tritiated substrate to follow its
catabolic pathway. This in vitro experimental system was
compared to the situation in vivo, represented by a series of
cell types of various regeneration capacities exposed to
prolonged ERT after longstanding disease course. Extreme
counterpart to cultured fibroblasts was represented by
cardiocytes, postmitotic cells, modified by longstanding
spontaneous storage.
This is also the first study focused on delivery of the
applied α-GALA into the storage cardiocytes which may
contribute to better understanding of the factors responsible
for the limited effectiveness of ERT in vivo.
Patients
For details of examined patients, their ERT regime, and the
biopsy samples, see Table 1.
Materials and methods
The study was approved by the Ethics Committee of the
General Teaching Hospital and the First Faculty of
Medicine, Charles University (60/2003F), Prague. Cardiac
biopsy samples were taken during coronary surgeries.
Written informed consent was obtained from patients
included in the study.
Cell lines Four fibroblast cell lines of patients with classic
type of Fabry disease (mutations in the GLA gene:p.
Q280K, p.R342Q, c.801ins36, c.delEx2 (c.195−?−369+?
del)) came from the cell culture depository of the Institute
of Inherited Metabolic Diseases. Fibroblasts with mutations
c.801ins36 and p.Q280K were from patient 1 and patient 2,
respectively, who underwent heart biopsy later on. All cell
lines (including p.R342Q and c.delEx2) were derived from
skin biopsies taken several years before ERT from patients
with classical form of the disease.
Recombinant α-galactosidases A REPLAGAL (agalsidase
alpha,agiftfromShireHumanGeneticTherapies,Cambridge,
MA, USA) sample no. 001-0229 was used withoutanyfurther
modification (dilution 1mg/ml solution). FABRAZYME
(agalsidase beta, a gift from Genzyme, Cambridge, MA,
USA) batch no. H0214AM, diluted according to manufac-
turer’s recommendation to 5mg/ml and then further diluted to
1mg/ml with redistilled water.
Experiments in cell cultures Cultured skin fibroblasts were
grown in accordance with standard protocols in Dulbecco’s
modified Eagle’s medium (DMEM) and 10% bovine fetal
serum (BFS).
Preparation of substrate The globoside, Gb4Cer, was
isolated from human erythrocyte membranes, characterized,
and tritium-labeled at the ceramide moiety (330MBq/mg).
The (
3H)Gb4Cer was incorporated into liposome particles
(a mixture of phosphatidylcholine, α-tocopherol, and
phosphatidic acid, Sigma, Czech Republic) and coated with
apoprotein E [2].
Feeding assays DMEM, 3 ml per 25-cm
2 flask, with 1%
BFS and radiolabeled glycolipid (3.3 × 10
6dpm/1ml) was
applied to nearly confluent Fabry fibroblasts and incubated
in a 5% CO2 incubator for 3days [2].
Uptake of enzyme Three milliliters of the enzyme solution
(1.32μg of enzyme per milliliter, final activity 3.8μmol
MU mg
−1.h
−1, the same for both enzymes) were placed in
fresh DMEM containing 10% heat-inactivated BFS and
applied to cells in 25-cm
2 flasks. The flasks were then
incubated for different periods of time. At least two 25-cm
2
flasks were analyzed for each time period/enzyme combi-
nation (0, 12, 24, 48, 96, and 192 h).
Analysis of (
3H)Gb3Cer degradation Three milliliters of
the enzyme solution (0.66μg of enzyme per milliliter,
final activity 1.9μmol MU mg
−1 h
−1, the same for both
enzymes) were placed in fresh DMEM containing 10%
heat-inactivated BFS and conduritol B epoxide (final
concentration 100mM, Calbiochem-Novabiochem GmbH,
652 Virchows Arch (2008) 452:651–665Germany) and applied to cells in 25-cm
2 flasks preloaded
with (
3H)Gb4Cer and incubated for different periods of
time. Analyses were performed at least in two 25-cm
2
flasks for each time period/enzyme combination (0, 9, 14,
19, and 24 h).
Cell harvesting and homogenization The fibroblasts were
harvested by trypsinization. The cell pellets were homog-
enized in distilled water in a cuphorn sonifier filled with ice
for 3 × 10s (Ultrasonic homogenizer 4710, Cole-Parmer,
Chicago, IL, USA, 40% output). Protein concentration [16],
enzyme activities, and uptake of the (
3H)Gb4Cer tracer
were determined in homogenate aliquots.
Enzyme assay The activity of α-GALA was assayed in
culture medium and in cell and tissue homogenates
according to the modified method of Mayes et al. [27].
Briefly, the reaction mixture contained 5mM of substrate,
4-methylumbelliferyl(MU)-α-D-galactopyranoside (Sigma,
Germany), in citrate buffer (pH 4.5). For cell and tissue
homogenates,the reactionalsocontained100mM α-N-acetyl-
D-galactosamine to inhibit α-N-acetylgalactosaminidase
activity. The complete reaction mixture was incubated for
30min at 37°C, and the fluorescence of the released 4-MU
was measured at excitation 365nm and at emission 448nm
on a luminescence spectrometer (Perkin Elmer LS50B,
Wellesley, USA).
Extraction and thin-layer chromatography analysis of (
3H)
glycosphingolipids
The remaining cell homogenate was extracted with
chloroform–methanol (2:1, v/v), and the lipids were
separated on thin-layer chromatography (TLC) plates
(Silica gel, Merck, Germany) using chloroform–methanol–
water (70:30:05, v/v/v) as the solvent system. Chromato-
grams were evaluated using a TLC linear radioactivity
analyzer (Raytest, Germany) [2].
Immunofluorescence labeling Fibroblasts were grown on
glass coverslips to near-confluence using standard meth-
ods. The cells were then grown for an additional 24h in
DMEM containing 10% of heat-inactivated BFS and
0.66μg/ml of the recombinant enzyme.
For the experiments using mannose-6-phosphate (M-6-
P) receptor blocking, the M-6-P (Sigma, Germany) was
added to the medium together with the enzymes to yield a
final concentration 10mM. Cells were fixed for 10min in
ice-cold methanol before immunodetection and non-
specific binding was blocked with 5% BFS. Recombi-
nant agalsidases were detected using rabbit polyclonal
antibody against human α-GALA TK88 (anti α-GAL,
TKT, Cambridge MA, USA) diluted to 9μg/ml, while
cathepsin D was detected simultaneously using mono-
clonal mouse antibodies (Serotec, Oxford, UK) diluted to
Table 1 Patients’ data
Patient Age Phenotype Mutation
in the
GLA gene
α-GALA activity
c in
nmol MU mg
−1 protein
h
−1 WBC skin
fibroblasts
Biopsy
before ERT
(year)
Biopsy in the course
of ERT: Fabrazyme
TM
(duration in months)
LV mass (g)
before ERT
LV mass (g) in
the course of ERT
(year of examination)
15 9
a Classical c.801ins36 0.19(0.4%) 0.63(1.3%) Skin
(1998)
LV (6) saphenous v.(21)
heart auricle(21) biopsy
taken 3 days after last
infusion
440
(2002Jul)
472 (2003Mar)
817 (2004Jun)
910 (2006Feb)
840 (2007May)
25 0
a Classical p.Q280K 0.13(0.3%) 0.95(1.9%) Skin
(1980)
Heart auricle (65) skin (65)
skeletal muscle (65) biopsy
taken 2 days after last
infusion
338
(2001Jan)
404 (2002Jun)
340 (2004Sept)
423 (2006Jan)
583 (2006Jun)
521 (2006Dec)
36 0
b Classical p.H46Y 0.14(0.3%) –– ND –
LV (left ventricle) mass was measured by echocardiography according to Sahn DJ et al., Circulation 58 (1978), pp 1072–1083.
Clinical details and ERT regime: Patient 1 underwent two coronary bypass graft surgeries (April 2003, June 2004). Patient 2 underwent coronary
bypass surgery in November 2006. Both patients were treated by Fabrazyme (dosage, 1 mg/kg every 2 weeks); patient 1 since October 2002 and
patient 2 since July 2002. Biopsy was taken on the third day after the protocolar infusion of Fabrazyme in patient 1 and on the second day after the
infusion in patient 2. Patient 3 underwent renal transplantation in 1993 and was treated by ERT (Replagal 0.2 mg/kg every 2 weeks) for 3 years
since September 2001. ERT was withdrawn 1 year before death because of advanced dementia.
ND not determined
aAge when heart auricle biopsy was performed
bAge at death. Only frozen autopsy samples of the heart were available for analysis which substituted approximate status without ERT.
cDetermined before ERT, control range for WBC 24.8–75.7 nmol MU mg
−1 protein h
−1 (n=65); for skin fibroblasts 33.8–70.8 nmol MU mg
−1
protein h
−1 (n=13)
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anti-Gb3 (CD77) antibody (BGR23, code 370680,
Seikagaku, Japan) diluted to 6.7μg/ml after 10min
fixation with 4% phosphate-buffered paraformaldehyde
and blocking with 5% BFS. The primary antibodies
were visualized using Alexa Fluor 488-conjugated goat
anti-rabbit IgG, Alexa Fluor 488-conjugated goat anti-
mouse IgG and Alexa Fluor 568-conjugated goat anti-
rabbit IgG (Molecular Probes, Invitrogen, Carlsbad, CA,
USA). The samples were examined using two Nikon
confocal microscope setups (1) Nikon C1, Eclipse E800
microscope equipped with a laser scanning confocal
head (Nikon, Japan) and a Nikon 60X, NA 1.4 oil
immersion objective or (2 Nikon C1si LSM head
mounted on TE-2000 inverted microscope and with
Nikon TIRF NA 1.49 60× oil immersion objective. All
channels were recorded separately to avoid cross-talk
between channels. The co-localization analysis was
performed with representative images using ImageJ
software [31] with JaCoP plugin [4] and Huygens image
analysis software (SVI, Hilversum, The Netherlands). The
degree of co-localization was assessed by coefficients
described by Manders et al. [26]. Two independent
experiments were done to support the results.
The image acquisition conditions were kept constant in
all parameters for samples presented in Fig. 3e–h.
Histochemical and ultrastructural analyses of tissue sam-
ples Patient 1. The sample of superficial part of the left
cardiac ventricle biopsied after 6months of ERT was
processed for electron microscopy. Specimens of the heart
auricle and part of the saphenous vein graft taken after
21months of ERT were transferred to the liquid nitrogen
and stored on dry ice.
Patient 2. Samples of the heart auricle, skin, and skeletal
muscle taken after 65months of ERT were frozen in liquid
nitrogen or fixed with phosphate-buffered paraformalde-
hyde (Fluka, Buchs, Switzerland). Samples for standard
ultrastructural analysis were fixed with 10% paraformalde-
hyde overnight, post-fixed in phosphate-buffered 1%Os04,
dehydrated and embedded into Epon-Araldit mixture.
Samples for electron microscopic immunostaining were
fixed with 4% paraformaldehyde for 2 h, dehydrated, and
embedded into LR White resin (London Resin Company,
Reading, England). Skin biopsies taken before ERT start
from both patients were processed for standard electron
microscopy. Patient 3 (death one year after ERT termina-
tion). Postmortem frozen and resin embedded samples from
the left cardiac ventricle were included into the study to
substitute approximate status before ERT.
Cryostat sections were prepared from the frozen samples
and used for immunohistochemical evaluation of the
lysosomal storage status (Gb3Cer storage, lipopigment
accumulation) for detection of the applied agalsidase protein
and for histochemical evaluation of its activity.
Lysosomal storage status Gb3Cer storage was detected in
cryostat sections after pretreatment with cold anhydrous
acetone (at 4°C) for removal of possible apolar lipid
admixture and for glycolipid fixation. They were briefly
post-fixed with 4% buffered paraformaldehyde (for 5min at
4°C). After standard blockade of endogenous peroxidase
(with sodium azide and H2O2) and non-specific protein–
protein interactions (with 5% BFS), the sections were
incubated with monoclonal mouse anti-Gb3Cer antibody
diluted 1:100 in 5% BFS (at 37°C for 1h or at 4°C
overnight). Detection of bound primary antibody was
achieved using EnVision + System-HRP Anti-Mouse
(DakoCytomation, Glostrup, Denmark) and the DAB +
Chromogen kit (K 3460, DAKO Cytomation, Carpinteria,
USA). The staining specificity was checked using total lipid
extraction by chloroform (C)–methanol (M)–water (W)
4:8:3, followed by C–M 2:1 (each step for 30min at room
temperature). The sections were rinsed in methanol, briefly
fixed in paraformaldehyde, and used for the lipid immuno-
detection. Lysosomal storage status was also studied by
birefringence of liquid crystals of the stored polar lipid and
by detection of lipopigment autofluorescence. The latter
was evaluated by epifluorescence microscopy using the
Nikon BV-2A filters blocks (EX 400-440, DM 455, BA
470). The best results were obtained after brief (5min) pre-
extraction of the lipids with C–M mixture (1:1, v/v)t o
prevent moderate non-specific autofluorescence of the
stored lipid. The liquid crystalline state of the stored lipid
deposits exhibited considerable instability and was best
evaluated using Baker’s fixative solution. The results were
compared with samples from age-matched controls. Neutral
term lipopigment was used throughout the manuscript
because of ambiguous terminology [34].
Immunohistochemical detection of the applied enzyme
protein Cryostat sections were fixed with 4% phosphate-
buffered paraformaldehyde exposed to standard blocking
procedures (see above) and incubated for 1h at 37°C with
the primary polyclonal antibody TK 88 diluted to 4.5μg/ml
in 5% FCS then washed in PBS and exposed to the
detection kit (EnVision + System-HRP Anti-Rabbit, Dako-
Cytomation). An alternative fixation of sections using a
mixture of chloroform–acetone (1:1, v/v) for 30min at room
temperature followed by paraformaldehyde was used for
some of the experiments. Semi-thin 0.5-μm sections
embedded into LR White medium were treated with citrate
buffer pH6.0 for 40min at 90°C and incubated after the
aforementioned blocking procedures with TK88 antibody
for 1h at 37°C and thereafter treated with the detection kit
as described above.
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α-GALA were counterstained with Harris hematoxylin
and mounted into the Immu-Mount medium (Shandon,
Pittsburgh, PA, USA) which allowed simultaneous evalu-
ation of the presence of the applied enzyme (eventually
Gb3Cer), birefringent lipid and autofluorescent lipopigment.
Histochemical detection of in situ enzyme activities Activ-
ity of α-GALA was evaluated using both the post-coupling
technique with 6-bromo-2-naphthyl-α-D-galactopyranoside
(LaChema, Brno, Czech Republic) and Fast Blue B and
the simultaneous azo-coupling technique with 1-naphthyl-
α-D-galactopyranoside (Koch Light, Colnbrook Bucks,
UK) and hexazonium pararosaniline; both were done on
semi-permeable membranes allowing to detect activities of
both bound and soluble enzymes according to the published
prescriptions [24]. Semi-permeable membrane technique
was used for demonstration of activities of β-galactosidase
(indigogenic method), β-glucuronidase, and acid phospha-
tase (simultaneous azo-coupling method using in both cases
naphthol ASBI-type substrates and hexazonium pararosan-
iline). Acid phosphatase activity was also demonstrated
using the aqueous medium [24].
Mannoso-6-phosphate receptor (MPR, cation-independent)
was detected using monoclonal antibody (2G11 clone,
Abcam, Cambridge, UK), diluted 1:400. Polyclonal antibody
against cathepsin D was purchased from DAKO and used in
dilution 1:200. In both cases, the incubation was overnight at
4°C.
Results
Studies in cultured mutant cells
Uptake of recombinant enzymes into cultured Fabry cells
and efficiency of Gb3Cer hydrolysis
To monitor the function of agalsidases in situ, the uptake
into Fabry fibroblasts was measured over the course of
192 h (8days). Both enzymes were similarly internalized
into the cultured cells, with maximum activity at 24h
incubation. The uptake of agalsidase beta measured with
MU-substrate was 2.5-fold greater than that of agalsidase
alpha, although the enzymes were applied at the same
concentration (1.32mg/ml medium). This result was con-
firmed by repeated experiments on three different Fabry
fibroblast cell lines. After 24h, the cellular activities of both
enzymes started to decline. However, even after 8days, the
values exceeded several times the normal activity of healthy
cells (Fig. 1). Activity in the culture medium decreased
equally in both agalsidases, falling to 4–6% of its original
value (Fig. 1, inner graph).
The correction of the defect in Fabry cells was monitored
with natural substrate in mutant cell cultures pre-loaded with
tritium-labeled globoside (
3H)Gb4Cer, the (
3H)Gb3Cer pre-
cursor. The quantity of degradation products calculated from
TLC-radioactivity scans reflected approximately the uptake
tendencies of the respective enzymes (Fig. 2). Despite the
differences in uptake (Fig. 1), both loaded agalsidases proved
efficient in intra-lysosomal degradation of Gb3Cer.
Confocal microscopic examination of internalized
agalsidases with endosomal/lysosomal markers in cultured
Fabry cells
Fabryfibroblasts were incubatedwith recombinant agalsidases
for 24h. The intracellular distribution of agalsidase alpha and
agalsidase beta in the cells was detected by anti α-GALA
antibody (red channel, Fig. 3a,b). The lysosomes were
visualized in the perinuclear region by immunodetection of
cathepsin D (green channel, Fig. 3a,b). In a similar manner,
the localization of intracellular Gb3Cer deposits was
correlated with recombinant enzymes internalized into α-
GALA deficient fibroblasts (Fig. 3g,h). The merger of the
agalsidase and cathepsin D signals suggested lysosomal
localization of loaded recombinant enzymes and was further
documented by co-localization maps (Fig. 3c,d). Correlation
of agalsidase signal with lysosomal transmembrane protein
LAMP 2 was also demonstrated (data not shown).
Endogenous enzyme protein was not detected in the cells
of Fabry patients (data not shown). The addition of M-6-P
to the culture medium, together with agalsidases, strongly
Fig. 1 Internalization of recombinant α-galactosidases A (agalsidases
alpha and beta) into Fabry skin fibroblasts as a function of time.
Recombinant enzymes (1.32 μg of enzyme protein per milliliter of
medium) were applied into cultures of Fabry cells incubated under
standard conditions. After 0, 12, 24, 48, 96, and 192 h, medium was
removed, cells harvested, and analyzed in vitro with MU-substrate as
described in “Materials and methods”. Each value is average of
duplicate flasks. Intracellular agalsidase beta activity exceeded 20
times normal levels at the maximum (24 h), while agalsidase alpha
activity was eight times the normal value in healthy cells (50.3±
13.6 nmol MU mg
−1 protein h
−1 in controls, see broken line). Insert is
a time course of agalsidases stability in the culture medium
Virchows Arch (2008) 452:651–665 655inhibited the uptake of both enzymes (Fig. 3e,f), confirming
that M-6-P receptor endocytosis is a major pathway of
agalsidase transport into fibroblasts. The double labeling of
Gb3Cer (Fig. 3g,h, green channel) and recombinant
enzymes (Fig. 3g,h, red channel) did show only a few
granular structures containing non-degraded Gb3Cer which
were still present. The co-localization map of Gb3Cer and
recombinant enzymes (Fig. 3i,j) showed only limited
overlap (compare logarithmically color coded overlap
coefficient in co-localization maps of Gb3Cer/α-GALA
and CatD/α-GALA).
Studies in tissues
In vitro α-GALA activity in the heart samples
α-GALA activity determined in the auricular sample of the
patient 1 was 1.53 vs. 10.18±2.32 nmol MU mg
−1 protein
h
−1 in controls (n=5). This value represented 15% of the
normal activity of the enzyme in the auricular part of the
heart which implies slight increase from deficient values.
There was no representative sample of the heart auricle in
patient 2 for biochemical analysis. Residual enzyme
activity in the autopsy sample (patient 3) was barely
detectable (0.12 nmol MU mg
−1 protein h
−1, i.e., about
1% of the control mean).
Immunohistochemical and ultrastructural studies
Evaluation of the lysosomal storage status Before ERT,
dermal capillaries (skin biopsy available in patients 1 and 2)
displayed lysosomal storage (Fig. 4a). ERT led to complete
clearance of the capillary endothelium lysosomes already
after 6 months (patient 1) from the stored lipid and to
retraction of the originally expanded system to normal
dimensions (Fig. 4b,c). Capillary basement membranes
were thin and single. Capillary endothelial storage in
various degrees was detectable in the postmortem heart
specimen of the patient who died 1 year after ERT
withdrawal (Fig. 4d).
The auricular cardiocytes in both patients on ERT
displayed variable, but on average high degree, Gb3Cer
storage concentrated in the large perinuclear region
(Fig. 5a). Lipid storage was paralleled by increase in
lipopigment (Fig. 5c). Cardiocytes free of lysosomal lipid
storage and containing only lipopigment were rare, and
those free of both lipid and lipopigment were exceptional.
The postmortem heart specimen displayed massive and
uniform lipid storage occupying the bulk of the cardiocyte
cytoplasm (Fig. 5b). Lipopigment was present in the form
of dispersed tiny granules (Fig. 5d). Ultrastructure of
cardiocytes, studied in all three cases, showed numerous
lysosomes with varying degrees of aggregation and fusion
with deposits of loosely or densely packed lipid mem-
Fig. 2 Degradation of (
3H)Gb3Cer by Fabry fibroblasts loaded with
(
3H)-globoside after application of agalsidases alpha and beta.
Illustration of 24-h experiments (example of one experimental set
from three is shown). (
3H)-globoside (5×10
6 dpm), precursor of (
3H)
Gb3Cer, was incorporated into the liposomes coated with Apo E and
added to the culture medium as described in “Materials and methods”.
After 3 days of incubation, the agalsidases were applied at final
activity of 1.9 μmol ml
−1 h
−1. After 0, 9, 14, 19, and 24 h, cells were
harvested, the lipids extracted, separated by high performance thin
layer liquid chromatography, and the products were quantified by TLC
linear radioactivity analyzer (“Materials and methods”). Percentage of
degradation products was calculated from TLC scans in relation to
total cell radioactivity comprising substrate (
3H)Gb3Cer and the sum
of its degradation products partially transformed into products of re-
synthesis (phospholipids)
 Fig. 3 Co-localization of internalized agalsidase alpha (a–i) and
agalsidase beta (b–j) with cathepsin D and Gb3Cer in the Fabry
fibroblasts after 24-h incubation (a, b) Confocal analysis of cells
labeled for α-galactosidase A (α-GALA, red) and intra-lysosomal
marker cathepsin D (CatD, green) displayed granular distribution of
both signals and their parallel considerable overlap. Mander’s
coefficients MGAL and MCatD ranged from 0.209 to 0.441 and 0.53
to 0.849 in the images, respectively. MGAL and MCatD coefficients
represent the fraction of co-localizing pixels from the overall number
of pixels with intensity values above the given threshold calculated for
the particular image channel. Threshold levels to filter background
were set to 10% of the pixel intensity range in both channels. The co-
localization of both signals is also illustrated by co-localization maps
(c, d) employing overlap coefficient values (0–1), color coded by
lookup table placed under this panel. Addition of 5 mM of M6P to the
culture medium completely blocked the α-GALA transport to the
lysosomes (e, f) and changed the signal of α-GALA from granular
(intra-lysosomal) pattern to diffuse low-intensity signal virtually
inseparable from nonspecific background. The co-labeling of α-
GALA and Gb3Cer in the cultured fibroblasts of Fabry patients
incubated 24 h with recombinant agalsidases showed very limited
overlap (g, h). The distribution of co-localization of both signals is
also demonstrated by co-localization map of overlap coefficient (i, j).
Comparing images (g, h) and (i, j) demonstrates minimal correlation
of α-GALA and Gb3Cer signals in the cells. This observation
suggests that the population of lysosomes with strong α-GALA
detection has already been cleared off Gb3Cer. Scale bars in f (valid
for e, f) and j (valid for a–d and g–j) correspond to 10 μm
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its (Fig. 6a). In patient 2, there were exceptional
cardiocytes with discrete lysosomal lipid storage but with
numerous small lucent vesicles, suggesting relatively
effective lysosomal clearance (Fig. 6b).
In all cases, irrespective of the ERT, the vascular smooth
muscle cells displayed marked lipid storage. Persistent
storage was seen in the skin eccrine glands (Fig. 7a) in
pericytes and stromal fibroblasts, especially those in the
hair bulb matrix (Fig. 7b). Discrete storage was found in the
skeletal muscle fibers (not shown here). In the sample of
the saphenous vein graft, there was prominent lipid storage
in intimal cells and in the smooth muscle cells of the tunica
media (Fig. 7c), which also displayed hypertrophy and
hyperplasia. Endothelial cells of the tunica intima were free
of storage, as were the endothelial cells of the adventitial
vessels.
Storage in some cell types was accompanied by increase
in lipopigment (mostly in the cardiocytes, skeletal muscle,
but almost absent in the smooth muscle cells). Electron
microscopy showed densely packed lipid membranes and
pleiomorphic structure of the lipopigment in lysosomes.
Evaluation of the intracellular delivery of the applied
enzyme In situ immunodetection of the applied enzyme
performed in heart samples of the ERT-treated patients
showed relatively strong signal of variable intensity in a
majority of cardiocytes (Fig. 8a). Simultaneous detection of
both the immunostained agalsidase protein and the stored
birefringent lipid/lipopigment in a single section showed
the coexistence of both the targeted enzyme and lipid
storage in a very close contact in the majority of cardiocytes
(Fig. 8c). More intimate contact between the targeted
enzyme and the storage compartment was seen after brief
extraction of the stored lipid with chloroform–acetone
mixture (see “Materials and methods”; Fig. 8d). Unfortu-
nately, the applied enzyme proved to be fixation sensitive,
so that our attempts to define its relation to the storage
compartment at the ultrastructural level failed. However, in
semi-thin sections exposed to intensive antigen retrieval,
there were numerous positive granules of the applied
enzyme interspersed between autofluorescent lipopigment
granules (Figs. 8e,f). Both enzyme histochemical techni-
ques (see “Materials and methods”) showed the presence of
active enzyme in the storing cardiocytes (Fig. 9a). There
was also a close relation of the enzyme product to the
storage lysosomal compartment better seen in simultaneous
azo-coupling technique. Strong immunohistochemical
signal for the enzyme protein was seen in the vascular
and endocardial endothelium and in the epicardial meso-
t h e l i u mi nb o t hp a t i e n t so nE R T .N e i t h e rt h ee n z y m e
protein nor its activity was detectable in cardiocytes in the
Fabry postmortem heart sample without ERT (patient 3;
Figs. 8b, 9b).
Other lysosomal enzymes in the cardiocytes The storage
atrial cardiocytes displayed strong and uniform induction of
acid phosphatase activity (Fig. 10a). In contrast, induction
of β-galactosidase activity was highly irregular (Fig. 10b).
Activity of β-glucuronidase was barely detectable. Activ-
ities of the above enzymes in autopsy samples were
uniformly low.
Fig. 4 Ultrastructure of the storage in the heart capillary endothelium.
a Capillary endothelium with prominent storage before ERT. Patient 2
(bar 2 μm). b Capillary endothelium free of storage after 65 months of
ERT. Persisting storage in pericapillary cells. Patient 2 (bar 4 μm). c
Detail of the capillary endothelium after 6 months of ERT with
discrete lysosomal system containing unspecific lipopigment. Patient 1
(bar 2 μm). d Lysosomal storage in the capillary endothelium of the
heart after 1 year of ERT termination. This picture represents extreme
in the wide range of capillary storage levels. Patient 3 (bar 2 μm)
658 Virchows Arch (2008) 452:651–665Signals of both MPR (Fig. 10c) and cathepsin D (not
shown) in the biopsy samples were remarkably heteroge-
neous in storage cardiocytes ranging from barely detectable
to very strong intensities.
Discussion
Studies in cell culture Higher uptake of beta- than alpha-
agalsidase reflected greater number of phosphorylated
Fig. 6 Ultrastructure of the car-
diocyte storage. a Patient 2.
Atrial cardiocytes after
65 months of ERT with numer-
ous individual lysosomes accu-
mulating lipid dominating over
lipopigment (bar 2 μm). b Ex-
ceptional finding in the same
patient showing only discrete
lipid storage lysosomes. There
are numerous small vesicles
with lucent content, which most
probably represent cleared lyso-
somes (bar 2 μm)
Fig. 5 Persisting lipid storage in cardiocytes. a, b Immunohistochem-
ical demonstration of Gb3Cer. a Cardiocytes of the heart auricle
(patient 2) after 65 months of ERT (bar 100 μm). b Cardiocytes of the
left ventricle. Autopsy (patient 3) 1 year after ERT cessation. Insert
shows absence of Gb3Cer staining in control cardiocytes (bars
100 μm). Note certain degree of variability of storage, reflecting
parallel excessive lipopigment deposition. c, d Increase of the
autofluorescent lipopigment demonstrated after brief lipid extraction
with C–A. c Large lipopigment clusters in heart auricle cardiocytes
(patient 2). Insert: age-matched control (bars 100 μm). d Cardiocytes
in the left ventricle (patient 3) with dispersed numerous discrete
lipopigment granules (bar 100 μm). Insert: age-matched control
showing coarser lipopigment granules restricted to the perinuclear
region (bar 50 μm)
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presumed principal role of MPR-mediated endocytosis [18]
in skin fibroblasts which are receptor-rich. The complete
inhibition of cellular uptake of both agalsidases by M-6-P is
in accord with this conception.
Lysosomal targeting of the applied active enzyme was
double-checked. Firstly, successful targeting of enzyme
therapeutics to lysosomes has been proven through co-
localization with lysosomal marker cathepsin D. Evaluation
of images based on calculation of correlation and co-
localization coefficients pointed to slightly lower co-
localization parameters for the alpha compared to the beta
enzyme.
It must be pointed out that enzyme endocytosis and
trafficking via early to late endosomes is a dynamic
process. Therefore, only partial co-localization with
lysosomal markers can be achieved under the condition
of continuous enzyme supply. Final evaluation of
Gb3Cer and α-GALA signals in Fig. 3i,j strongly
suggested that lysosomes in fibroblast population were
almost cleared of substrate after 24-h incubation with any
of the enzymes.
Secondly, the delivered enzyme was shown to degrade
efficiently the natural substrate (
3H)Gb3Cer produced
directly in lysosomes from its radiolabeled precursor (
3H)
Gb4Cer. The exact quantification of lysosomal (
3H)Gb3Cer
degradation in situ confirmed indirect observation that
recombinant agalsidases degrade accumulated Gb3Cer in
a dose-dependent manner [33].
In situ (
3H)Gb3Cer degradation revealed lower differ-
ences between the two enzymes than in vitro assay with
soluble MU-analog using the whole homogenate of
agalsidase-loaded fibroblasts. This may be related to the
intracellular transport and unspecified location of agalsidase
in in vitro assay and to the availability of Sap B in
lysosomes when supply of enzyme is high.
However, despite the different degree of agalsidase
endocytosis, the cell-associated activity of both enzymes
exceeded by several times the α-GALA activity of normal
healthy cells (see Fig. 1), and both were found effective in
cleavage of (
3H)Gb3Cer. Their stability in the medium was
found identical in accordance with findings in blood plasma
[33].
Our experiments demonstrated effective targeting of the
applied enzyme to fibroblast lysosomes using both co-
localization and cleavage of its substrate locally produced
from its exogenously added precursor. (
3H)Gb4Cer was
used for the first time as an intra-lysosomal tracer of
function of recombinant agalsidases that does not increase
the substrate load and can serve as a model system for
evaluation of catabolic lysosomal functions and their
defects.
To sum up, the ERT is effective in the cultured fibroblast
system. In our view, it is because Fabry fibroblasts
represent a short-lived dynamic cell population unmodified
by low degree of spontaneous storage. Such cells exposed
transiently to a trace amount of labeled substrate can
effectively endocytose the recombinant enzyme. The
Fig. 7 Persisting storage in other cell types. a, b Patient 2 (ERT
65 months). Birefringent stored lipid in eccrine skin glands (a)( bar
100 μm) and in hair follicle matrix fibroblasts (b)( bar 50 μm). c
Patient 1 (21 months on ERT). Graft of saphenous vein used for
coronary artery reconstruction with massive birefringent deposits of
the stored lipid (bar 100 μm)
660 Virchows Arch (2008) 452:651–665Fig. 8 Immunohistochemical detection (TK 88 antibody) of α-GALA
protein in cardiocytes. a Strong signal for the enzyme protein in atrial
cardiocytes in patient 1 (21 months on ERT; bar 100 μm). b Absence
of signal in ventricular cardiocytes in patient 3 (1 year after ERT
withdrawal). Insert: signal for endogenous α-GALA in control
ventricular cardiocytes (bars 100 μm). c Simultaneous immunohisto-
chemical detection of the enzyme and of the birefringent stored lipid
showing coexistence of both in same cells. Semi-crossed Nicols (bar
30 μm). d Immunohistochemical detection of the enzyme after brief
lipid pre-extraction shows close relation of the enzyme to the storage
compartment (bar 50 μm). e Immunohistochemical detection of the
enzyme in a semi-thin section of LR-White-embedded specimen (bar
20 μm). f The stained section was simultaneously examined under UV
to show lipopigment (unstained) which represents marker of the
storage compartment (bar 20 μm). c, d Patient 1; e, f patient 2
Virchows Arch (2008) 452:651–665 661enzyme is delivered to the storage compartment where it
exerts its degradative function. The whole process is
facilitated by easy access to the applied enzyme via MPR
and by the possibility to endocytose it along the entire cell
perimeter of unpolarized cell.
Studies in tissues Our study showed effective clearing of
endothelial cells by ERT corresponding to the published
results [21, 7, 36]. The design of our study allows us to
conclude that endothelial storage is resumed within 1 year
after cessation of ERT. In the Fabry disease mouse model,
the storage was resumed after several weeks of withdrawal
of the enzyme [21].
In contrast to endothelia, the storage persisted in a set of
cells despite the continuous ERT, e.g., in cardiocytes,
vascular smooth muscle cells, pericytes, some fibroblasts,
and perineurial cells, all repeatedly described to resist
substantial storage reduction by ERT [12, 40, 7, 39, 43, 32,
33, 36]. We may add skin eccrine glands, hair bulb
fibroblasts, and skeletal muscle. The design of the study
did not allow detecting possible diminution of the persisting
storage mentioned in some of the above-quoted reports. For
instance, the cardiocyte storage pattern in both our cases
admits partial clearance (Fig. 6b). Persistent storage in
cardiocytes was accompanied by a notable increase in
lipopigment which should be taken as irreversible. These
findings may explain the absence of cardiac improvement
in either patient on ERT (see Table 1).
It is not easy to explain the limited ERT effectiveness.
There is the undisputed role of the physical barriers,
represented by fibrous stroma and basal membranes,
especially when multiplied around capillaries [11]. Free
access of the applied enzyme to endocytotically active cell
perimeter in non-polarized cultured fibroblasts and through
fenestration in the liver sinusoidal endothelium to the
hepatocyte basolateral pole may contribute significantly to
the effective ERT [35] (also M.E. personal observation),
similarly as the number of MPR known to be of high
density in fibroblasts [42, 18]. However, the density of the
latter was not shown to correlate with the level of the
applied enzyme uptake [29]. In polarized storage cells
(epithelia, e.g., in the sweat glands, respiratory epithelium,
etc.), the applied enzyme uptake is restricted to the
basolateral pole. In case of renal tubules, both poles may
participate to different degree in various parts of the
nephron [38]. In the case of endothelial cells, the
reproducible effectiveness of ERT may be explained by
the barrierless access of the enzyme to the apical pole active
in endocytosis [37].
Our findings point to further potentially important facts.
Before all, it is the presence of the applied active enzyme
inside the storage cardiocytes in patients under ERT (not in
samples from patient 3 with ERT terminated). We base this
crucial finding on the following data. No enzyme protein
was immunohistochemically detectable in cultured mutant
fibroblasts of both patients. As the value of enzyme activity
in wild-type fibroblasts is much higher (approximately
fivefold) than in the heart, it excludes presence of
detectable amount of endogenous mutant enzyme in atrial
cardiocytes of the Fabry patients studied. This is in accord
with negative results in the heart from patient 3 with ERT
terminated (see Fig. 8b). The histochemically demonstrable
α-GALA activity in cardiocytes of ERT-treated patients
(and not in patient 3) fits perfectly with the conclusion
(Fig. 9). Similarly, increase in activity was shown by
biochemical assay in one auricular sample available. We
would also like to stress that in our studies, we used
cryostat sections because the enzyme was found to be
Fig. 9 Histochemical evaluation of α-GALA activity with simulta-
neous azo-coupling method. a Presence of enzyme activity in storing
atrial cardiocytes of patient 1 (21 months on ERT; bar 100 μm).
Compare with Fig. 8. b Absence of enzyme activity in ventricular
cardiocytes 1 year after cessation of ERT (patient 3). Insert shows
enzyme activity in control ventricular cardiocyte (bars 50 μm)
662 Virchows Arch (2008) 452:651–665remarkably fixation-sensitive (see below). Therefore, sen-
sitivity of our detection of the applied enzyme was higher
than that in previous reports [20, 29].
The sensitivity of the applied enzyme to aldehyde
fixation prevented its localization inside storage lysosomes
at the electron microscope level. However, results in both
cryostat and LR-White-embedded sections (Fig. 8a,d–f)
indicate at least partial successive delivery of the enzyme.
Its quantity may play a role, as the heart in Fabry disease
may express storage even in cases with relatively high
residual activity [30]. We would like to hypothesize that
there may be modification of membranes of the endosomal/
lysosomal compartment, induced by longstanding storage,
especially in cells with low regeneration potential, cardio-
cytes being an ideal example. Such modification could lead
to decreased effectiveness of the contact of the storage
compartment with the endocytotic delivery of the applied
recombinant enzyme. Decrease in MPR in many of the
storage cardiocytes suggests a changed proportion of
lysosomes to late endosomes, and this may result in altered
fusion, inevitable for delivery of the applied enzyme cargo
to the latter [8, 25]. It might also indicate disturbed contact
even with the Golgi apparatus, which might explain low
activities of β-glucuronidase, β-galactosidase, and cathep-
sin D in the cardiocyte storage compartment. Further,
parallel deposition of lipopigment (see above) points to
irreversible modification of storage lysosomes. Any rele-
vant comparison with the mouse model of Fabry disease is
difficult, as the mouse cardiocytes do not seem to display
storage regularly [21]. Nothing is known about the effective
interaction of the applied agalsidase with Sap B in Fabry
disease. The disorder, featured by densely packed lyso-
somal lipid membranes, differs substantially from the well-
defined physiologic conditions [22]. Decreased amount of
Sap B in Fabry disease [28] may aggravate the situation. In
sum, one of the critical factors in ERT of Fabry disease
may, thus, be the degree of storage and physical status of
the stored Gb3Cer and availability of Sap B. All this raises
an important question whether the effective targeting of the
enzyme to the storage cell is the only prerequisite for
effective ERT.
The last factor awaiting evaluation is the role of storage
cell turnover in Fabry disease (and in other lysosomal
storage disease). In the case of endothelial cells in Fabry
disease, preliminary results (J. Bultas, personal communi-
cation) showed its increase. Therefore, the positive effect of
ERT might be also explained as a replacement effect of
storage cells by the endothelial cell progenitors [1, 5, 17]
that may easily endocytose the applied enzyme and thus
prevent storage. This mechanism does not come into
consideration in the case of post-mitotic storage cells,
typically cardiocytes. Taken together, our observations
speak in favor of the strategy of early treatment to prevent
Fig. 10 Lysosomal enzyme activities and MPR immunostaining in
storage atrial cardiocytes. a High and uniform activity of acid
phosphatase (aqueous medium). Insert shows activity in controls
(bars 50 mm). b Heterogenous activity of β-galactosidase with
remarkably low values in some cardiocytes. Insert shows activity in
control cardiocytes (bars 50 mm). c Similarly heterogeneous signal for
MPR (bar 30 mm)
Virchows Arch (2008) 452:651–665 663development of storage and of irreversible modulation of
post-mitotic cells or of cells with low regeneration potential
(cardiocytes, smooth muscle cells) and of their lysosomes.
This would be the most effective prevention of irreversible
tissue changes. Studies on mouse model which would
compare effectiveness of early ERT (starting immediately
after birth) with its delayed application in adulthood are
desirable.
Conclusions
We suggest that future studies should focus on defining the
differences between the storage cell, the storage compart-
ment and their wild-type counterparts, and on possible
replacement of cell populations with higher turnover by
their enzyme supplied precursors. Then, enzyme replace-
ment treatment should probably be better conceptualized as
an enzyme preventive therapy (see also [19]).
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